Intra-Cellular Therapies — Merger or Acquisition (February 2025)
12 slides from Intra-Cellular Therapies's merger presentation, Feb 25, 2025

Slide 1: Legal Disclosure
Legal Disclosure ooking Statements Intra-Cellular Therapies, Inc. (“ITCI") by Joh The reader TCL ing} Pe y transacti distraction of i if completed, may take longer In adit dl ITCLA factors and Johi John . 10-K for tk 2024, 13, ud i and “Item 1A. Risk Factors,” Report on Form 10-K for the fiscal year

Slide 2: Legal Disclosure
Legal Disclosure Participants in the Soli \der SEC rules, “participants” PI on Form 10-K for 1023, whi i , 2024, and Johi stockholders, whi i 13, 2024. i i i 10-K for the year ended December 31, 2023, , 2024, i April 29, 2024. i 4, August 28, 2024, August joel S. Marcus on June 18, 2024 and June 25,

Slide 3: We're excited to join you today!
We’re excited to join you today! Jennifer Taubert John C. Reed, M.D., Ph.D. Executive Vice President, Executive Vice President, R&D Worldwide Chairman J&J Innovative Medicine J&J Innovative Medicine J&J {ONFIDENTIAL & PROPRIETAR NoT

Slide 4: Better together.
Better together. . Intra-Cellular Johnson © Intra-Cellular &Johnson CONFIDENTIAL:

Slide 5: Our Credo

Slide 6: Our legacy and leadership in neuroscience
Our legacy and leadership in neuroscience 20+ 4 $7.1B industry-leading medications on WHO sales in 2023! innovations Essential Medicines List RisperdalCONST’ Haldol’ Y Risperdal Vv g@Reminyl GCONCERTA Opncguranzn Oncoauarvens IRS tsovce cate Phame ww SoesbyPoeNUYASEEEN Negeri, Use ont

Slide 7: Significant opportunity to address unmet need for millions of patients
Significant opportunity to address unmet need for millions of patients Proven development and commercial capability driving CAPLYTA®, a differentiated commercialized therapy Robust and promising pipeline with best-in-disease potential, including ITI-1284 and additional opportunities from clinical an

Slide 8: Driving neuroscience innovation, together
Driving neuroscience innovation, together Significant unmet need remains >1 billion patients #1 cause of illness & Market to double worldwide disability by 2030 J&J has made ingful progress in ad ‘ing care Innovative SPRAVATO® ‘ion & ission for schizophrenia LAls monotherapy approval Nipocalimab gMG

Slide 9: Questions?
Questions?

Slide 10: Next steps & reminders
Next steps & reminders It remains business as usual. Until the transaction closes it remains business as usual, with J&J and Intra-Cellular Therapies operating as separate companies. At this time, please do not reach out to anyone at J&J. Integration plans are in development. In the weeks and months

Slide 11: Q&A
Q&A Jennifer Taubert John Reed, M.D., Ph.D. Tom Cavanaugh Executive Vice President, Worldwide Executive Vice President, R&D, Company Group Chairman, Chairman, innovative Medicine ive Medici North Ai i 2 Bill Martin, Ph.D. Dave Crutchfield Global ic Head, our Pnnaeh \ CONFIDENTIAL & PROPRIETARY. FOR

Slide 12: Cautions Concerning Forward-Looking Statements
Cautions Concerning Forward-Looking Statements This communication contains “forward-looking statements” regarding the acquisition of Intra-Cellular Therapies, Inc. (“ITCI”) by Johnson & Johnson. The reader is cautioned not to rely on these forward-looking statements. These statements are based on cu
Source: SEC EDGAR · DFAN14A filed Feb 25, 2025
